Combat Medical has been working since 2008 with a multidisciplinary team of urologists, nurses, medical engineers, production specialists and end users to develop a hyperthermic delivery system – known as COMBAT BRS, which combines with chemotherapy to treat certain types of Bladder Cancer. We are committed to providing an effective, accurate and affordable system that optimises the intravesical instillation of chemotherapy and achieves real measurable results.
Combat Medical is committed to investing in research and clinical evidence based studies to demonstrate the effectiveness of our technology in order to create a solid foundation for its use. HIVEC™ (Hyperthermic Intra-VEsical Chemotherapy) I and II prospective, randomised, international, multicentre clinical trials in 494 NMIBC intermediate risk patients are now underway – see HIVEC™ area for details of all our current trials. In the future Combat Medical will continue to invest in and initiate further studies and clinical trials in order to get conclusive information for better disease management.
The COMBAT BRS system has been CE marked and in clinical use since 2011, it is currently used in clinical practice in 33 countries globally. We partner with a network of local distributors to ensure that the COMBAT BRS system is available to bladder cancer patients all around the world, in order to deliver HIVEC™ treatment. We are constantly working towards increasing its availability on an international level.
Our offices in both the UK and Madrid are filled with an experienced team of enthusiastic individuals who all share the common goal of improving patient lives by developing innovative new technologies and treatments. We have all been personally selected to work for Combat by our founding members.
Combat Medical founders have over 20 years experience in developing and launching new innovative medical systems. Our team of engineers and designers are experts in the control of temperature management with over 30 years combined experience.